Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy

Clinical Breast Cancer

Volumn 3, Issue 1, 2002, Pages 45-51

  Demetri, George D ^a   Gabrilove, Janice L ^b   Blasi, Michael V ^c   Hill, Richrd J ^c   Glaspy, John ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Ortho McNeil Pharmaceutical Incorporated   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anemia; Breast cancer; Chemotherapy; Epoetin alfa; Erythropoietin; Quality of life

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG EFFECT; DRUG SAFETY; FATIGUE; FEVER; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SELF EVALUATION; SYMPTOM;

EID: 0036104275     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2002.n.011     Document Type: Review

References (34)

1. Combination chemotherapy for metastatic or recurrent carcinoma of the breast: A randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP
2. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer
3. Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response
4. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
5. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer
6. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
7. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
8. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
9. Multicenter UK audit of anemia in patients receiving cytotoxic chemotherapy
10. Quality of life during and after cancer treatment
11. Quality of life in cancer: Definition, purpose, and method of measurement
12. Quality of life in cancer: Definition, purpose, and method of measurement
13. Quality of life as an outcome of cancer treatment
14. Quality of life and the patient with cancer. Individual and policy implications
15. Fatigue in cancer patients
16. Fatigue and the cancer experience: The state of the knowledge
17. Fatigue in cancer patients: A review of the literature
18. Fatigue in women treated with bone marrow transplantation for breast cancer: A comparison with women with no history of cancer
19. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer
20. Fatigue in cancer and HIV/AIDS
21. Measurement of fatigue in cancer patients: Development and validation of the Fatigue Symptom Inventory
22. Correlates of fatigue in survivors of breast cancer
23. Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition
24. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey
25. Erythropoietin treatment of anemia associated with multiple myeloma
26. Recombinant human erythropoietin in the treatment of the anaemia of cancer
27. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin
28. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
29. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
30. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life
31. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
32. Sensitivity and accuracy of the visual analogue scale: A psychophysical experiment
33. Assessment of quality of life of patients with advanced cancer
34. Clinical applications of visual analogue scales: A critical review